Associated Papers
Nanobodies restore stability to cancer-associated mutants of tumor suppressor protein p16INK4a.
Burbidge O et al.
Structure (london, England : 1993), 2025
Functional characterization of all CDKN2A missense variants and comparison to in silico models of pathogenicity.
Kimura H et al.
Elife, 2025
Functional characterization of all CDKN2A missense variants and comparison to in silico models of pathogenicity.
Kimura H et al.
Biorxiv : the Preprint Server for Biology, 2025
NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma.
Ramakrishnan G et al.
Cell Reports, 2022
Sequence and Structure-Based Analyses of Human Ankyrin Repeats.
Chakrabarty B et al.
Molecules (basel, Switzerland), 2022
Molecular Characterization of Muellerian Tumors of the Urinary Tract.
Ortiz-Brüchle N et al.
Genes, 2021
CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study.
Lin JC et al.
Journal of Clinical Medicine, 2020
Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer.
Liu X et al.
Ebiomedicine, 2019
Cross-cancer profiling of molecular alterations within the human autophagy interaction network.
Lebovitz CB et al.
Autophagy, 2015
Integrated RNA and DNA sequencing improves mutation detection in low purity tumors.
Wilkerson MD et al.
Nucleic Acids Research, 2014
Comprehensive genomic characterization of squamous cell lung cancers.
Unknown Author
Nature, 2012
Classifying variants of CDKN2A using computational and laboratory studies.
Miller PJ et al.
Human Mutation, 2011
Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G et al.
The Journal of Investigative Dermatology, 2005
A minimum folding unit in the ankyrin repeat protein p16(INK4).
Zhang B et al.
Journal of Molecular Biology, 2000
Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.
Ruas M et al.
Oncogene, 1999
Stability and folding of the tumour suppressor protein p16.
Tang KS et al.
Journal of Molecular Biology, 1999
Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.
Arap W et al.
Oncogene, 1997
The CDKN2A (p16) gene and human cancer.
Foulkes WD et al.
Molecular Medicine (cambridge, Mass.), 1997
Defective folding of mutant p16(INK4) proteins encoded by tumor-derived alleles.
Zhang B et al.
The Journal of Biological Chemistry, 1996
Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.
Parry D et al.
Molecular and Cellular Biology, 1996
Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.
Quelle DE et al.
Cell, 1995